Targeting Cytotoxic Lymphocyte Antigen 4 (CTLA-4) in Breast Cancer

Overview

Journal Eur J Med Res

Publisher Biomed Central

Specialty General Medicine

Date 2024 Jul 3

PMID 38956700

Authors

Maryam Jama

Yasser Tabana

Khaled H Barakat

Affiliations

Soon will be listed here.

Abstract

Breast cancer (BC) has a high mortality rate and is one of the most common malignancies in the world. Initially, BC was considered non-immunogenic, but a paradigm shift occurred with the discovery of tumor-infiltrating lymphocytes (TILs) and regulatory T cells (Tregs) in the BC tumor microenvironment. CTLA-4 (Cytotoxic T-lymphocyte-associated protein 4) immunotherapy has emerged as a treatment option for BC, but it has limitations, including suboptimal antitumor effects and toxicity. Research has demonstrated that anti-CTLA-4 combination therapies, such as Treg depletion, cancer vaccines, and modulation of the gut microbiome, are significantly more effective than CTLA-4 monoclonal antibody (mAB) monotherapy. Second-generation CTLA-4 antibodies are currently being developed to mitigate immune-related adverse events (irAEs) and augment antitumor efficacy. This review examines anti-CTLA-4 mAB in BC, both as monotherapy and in combination with other treatments, and sheds light on ongoing clinical trials, novel CTLA-4 therapeutic strategies, and potential utility of biomarkers in BC.

Citing Articles

Divide and Conquer-Targeted Therapy for Triple-Negative Breast Cancer.

Nedeljkovic M, Vuletic A, Mirjacic Martinovic K Int J Mol Sci. 2025; 26(4).

PMID: 40003864 PMC: 11855393. DOI: 10.3390/ijms26041396.

Prognostic impact of metformin in solid cancer patients receiving immune checkpoint inhibitors: novel evidences from a multicenter retrospective study.

Wang J, Lin J, Guo H, Wu W, Yang J, Mao J Front Pharmacol. 2024; 15:1419498.

PMID: 39135791 PMC: 11317293. DOI: 10.3389/fphar.2024.1419498.

References

Autio K, Boni V, Humphrey R, Naing A . Probody Therapeutics: An Emerging Class of Therapies Designed to Enhance On-Target Effects with Reduced Off-Tumor Toxicity for Use in Immuno-Oncology. Clin Cancer Res. 2019; 26(5):984-989. PMC: 8436251. DOI: 10.1158/1078-0432.CCR-19-1457. View

Song Y, Lai L, Chong Z, He J, Zhang Y, Xue Y . E3 ligase FBXW7 is critical for RIG-I stabilization during antiviral responses. Nat Commun. 2017; 8:14654. PMC: 5355826. DOI: 10.1038/ncomms14654. View

Disis M, Stanton S . Triple-negative breast cancer: immune modulation as the new treatment paradigm. Am Soc Clin Oncol Educ Book. 2015; :e25-30. DOI: 10.14694/EdBook_AM.2015.35.e25. View

Mediratta K, El-Sahli S, DCosta V, Wang L . Current Progresses and Challenges of Immunotherapy in Triple-Negative Breast Cancer. Cancers (Basel). 2020; 12(12). PMC: 7761500. DOI: 10.3390/cancers12123529. View

Galluzzi L, Humeau J, Buque A, Zitvogel L, Kroemer G . Immunostimulation with chemotherapy in the era of immune checkpoint inhibitors. Nat Rev Clin Oncol. 2020; 17(12):725-741. DOI: 10.1038/s41571-020-0413-z. View

Zhu Y, Zhu X, Tang C, Guan X, Zhang W . Progress and challenges of immunotherapy in triple-negative breast cancer. Biochim Biophys Acta Rev Cancer. 2021; 1876(2):188593. DOI: 10.1016/j.bbcan.2021.188593. View

Taylor N, Vick S, Iglesia M, Brickey W, Midkiff B, McKinnon K . Treg depletion potentiates checkpoint inhibition in claudin-low breast cancer. J Clin Invest. 2017; 127(9):3472-3483. PMC: 5669567. DOI: 10.1172/JCI90499. View

Hashimoto M, Kamphorst A, Im S, Kissick H, Pillai R, Ramalingam S . CD8 T Cell Exhaustion in Chronic Infection and Cancer: Opportunities for Interventions. Annu Rev Med. 2018; 69:301-318. DOI: 10.1146/annurev-med-012017-043208. View

Snyder A, Makarov V, Merghoub T, Yuan J, Zaretsky J, Desrichard A . Genetic basis for clinical response to CTLA-4 blockade in melanoma. N Engl J Med. 2014; 371(23):2189-2199. PMC: 4315319. DOI: 10.1056/NEJMoa1406498. View

10.

Marwitz S, Scheufele S, Perner S, Reck M, Ammerpohl O, Goldmann T . Epigenetic modifications of the immune-checkpoint genes and in non-small cell lung cancer results in increased expression. Clin Epigenetics. 2017; 9:51. PMC: 5426039. DOI: 10.1186/s13148-017-0354-2. View

11.

Kwa M, Plottel C, Blaser M, Adams S . The Intestinal Microbiome and Estrogen Receptor-Positive Female Breast Cancer. J Natl Cancer Inst. 2016; 108(8). PMC: 5017946. DOI: 10.1093/jnci/djw029. View

12.

Mihic-Probst D, Reinehr M, Dettwiler S, Kolm I, Britschgi C, Kudura K . The role of macrophages type 2 and T-regs in immune checkpoint inhibitor related adverse events. Immunobiology. 2020; 225(5):152009. DOI: 10.1016/j.imbio.2020.152009. View

13.

Beavis P, Henderson M, Giuffrida L, Davenport A, Petley E, House I . Dual PD-1 and CTLA-4 Checkpoint Blockade Promotes Antitumor Immune Responses through CD4Foxp3 Cell-Mediated Modulation of CD103 Dendritic Cells. Cancer Immunol Res. 2018; 6(9):1069-1081. DOI: 10.1158/2326-6066.CIR-18-0291. View

14.

Darvin P, Toor S, Sasidharan Nair V, Elkord E . Immune checkpoint inhibitors: recent progress and potential biomarkers. Exp Mol Med. 2018; 50(12):1-11. PMC: 6292890. DOI: 10.1038/s12276-018-0191-1. View

15.

Orillion A, Hashimoto A, Damayanti N, Shen L, Adelaiye-Ogala R, Arisa S . Entinostat Neutralizes Myeloid-Derived Suppressor Cells and Enhances the Antitumor Effect of PD-1 Inhibition in Murine Models of Lung and Renal Cell Carcinoma. Clin Cancer Res. 2017; 23(17):5187-5201. PMC: 5723438. DOI: 10.1158/1078-0432.CCR-17-0741. View

16.

Gnjatic S, Bronte V, Rosa Brunet L, Butler M, Disis M, Galon J . Identifying baseline immune-related biomarkers to predict clinical outcome of immunotherapy. J Immunother Cancer. 2017; 5:44. PMC: 5432988. DOI: 10.1186/s40425-017-0243-4. View

17.

Watanabe T, Ishino T, Ueda Y, Nagasaki J, Sadahira T, Dansako H . Activated CTLA-4-independent immunosuppression of Treg cells disturbs CTLA-4 blockade-mediated antitumor immunity. Cancer Sci. 2023; 114(5):1859-1870. PMC: 10154808. DOI: 10.1111/cas.15756. View

18.

Zhang H, Xie W, Zhang Y, Dong X, Liu C, Yi J . Oncolytic adenoviruses synergistically enhance anti-PD-L1 and anti-CTLA-4 immunotherapy by modulating the tumour microenvironment in a 4T1 orthotopic mouse model. Cancer Gene Ther. 2021; 29(5):456-465. PMC: 9113929. DOI: 10.1038/s41417-021-00389-3. View

19.

Clavijo P, Moore E, Chen J, Davis R, Friedman J, Kim Y . Resistance to CTLA-4 checkpoint inhibition reversed through selective elimination of granulocytic myeloid cells. Oncotarget. 2017; 8(34):55804-55820. PMC: 5593525. DOI: 10.18632/oncotarget.18437. View

20.

Havunen R, Siurala M, Sorsa S, Gronberg-Vaha-Koskela S, Behr M, Tahtinen S . Oncolytic Adenoviruses Armed with Tumor Necrosis Factor Alpha and Interleukin-2 Enable Successful Adoptive Cell Therapy. Mol Ther Oncolytics. 2017; 4:77-86. PMC: 5363700. DOI: 10.1016/j.omto.2016.12.004. View